The surface protein CD133 is currently one of the best available markers for putative GSCs [24], thus we fractionized culture #18 with MACS accordingly and present several lines of evidence that MTH1 inhibitors decrease survival of the CD133 enriched and depleted fraction of GBM culture #18 equally well. This evidence concerns the gene PROM1 and glioblastoma.